Genfit SA
PAR:GNFT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Elbit Systems Ltd
TASE:ESLT
|
IL |
|
Kuniko Ltd
ASX:KNI
|
AU |
|
Thakral Corporation Ltd
SGX:AWI
|
SG |
|
Atom Hoteles Socimi SA
MAD:YATO
|
ES |
|
AgriFORCE Growing Systems Ltd
NASDAQ:AGRI
|
CA |
|
K
|
Kisan Mouldings Ltd
BSE:530145
|
IN |
|
M
|
Mitsui O.S.K. Lines Ltd
XBER:MILA
|
JP |
|
Ural'skaya Kuznitsa PAO
MOEX:URKZ
|
RU |
|
Greenland Resort Co Ltd
TSE:9656
|
JP |
|
R
|
Rane (Madras) Ltd
NSE:RML
|
IN |
|
VirnetX Holding Corp
NYSE:VHC
|
US |
|
UltraTech Cement Ltd
NSE:ULTRACEMCO
|
IN |
|
S
|
Sai Silks (Kalamandir) Ltd
NSE:KALAMANDIR
|
IN |
|
Refinaria de Petroleos de Manguinhos SA em Recuperacao Judicial
BOVESPA:RPMG3
|
BR |
|
Singularity Future Technology Ltd
NASDAQ:SGLY
|
US |
Genfit SA
Goodwill
Genfit SA
Goodwill Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Goodwill | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genfit SA
PAR:GNFT
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Goodwill
€18m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Sensorion SA
PAR:ALSEN
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Genfit SA
Glance View
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
